Zobrazeno 1 - 10 of 15 pro vyhledávání: '"Anna, Durigova"'
1
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection
Autor: Anna Durigova, Alice Cuenant, Krisztian Homicsko, Marie Vinches, Nadia Hayaoui, Marie Alexandre, Marie Viala, Luca Gianni, Diego Tosi, Céline Gongora, Caroline Mollevi
Publikováno v: British Journal of Cancer
British Journal of Cancer, Cancer Research UK, 2018, 118 (5), pp.679-697. ⟨10.1038/bjc.2017.473⟩
British journal of cancer, vol. 118, no. 5, pp. 679-697
International audience; BACKGROUND: Our previous survey on first-in-human trials (FIHT) of monoclonal antibodies (mAbs) showed that, due to their limited toxicity, the recommended phase II dose (RP2D) was only tentatively defined.METHODS: We identifi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b03f0a204474d74cee7ad53b33df4109
https://hal.umontpellier.fr/hal-02292921
Zobrazit plný text záznamu
2
Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies
Autor: Anna Durigova, Diego Tosi, Caroline Mollevi, Luca Gianni, Yassine Laghzali, Gianluca Del Conte, Nadia Hayaoui, Sophie Gourgou, Marie Alexandre, Krisztian Homicsko, Angelica Fasolo, Marie Vinches
Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2015, 33 (19), pp.2158-2165. ⟨10.1200/JCO.2014.58.1082⟩
Purpose We conducted a comprehensive review of the design, implementation, and outcome of first-in-human (FIH) trials of monoclonal antibodies (mAbs) to clearly determine early clinical development strategies for this class of compounds. Methods We p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da430cfa09d17700b6811f3de0bf73b5
https://doi.org/10.1200/jco.2014.58.1082
Zobrazit plný text záznamu
3
Abstract P4-07-08: Circulating miRNAs as surrogate markers for hormonosensibility in patients with hormone receptor-positive metastatic breast cancer? A pilot study
Autor: Anne Pradines, Gilles Favre, Thomas Filleron, Pauline Bringer, Henri Roché, Anna Durigova, M. Ouali, William Jacot, Magali Farella, Jean-Louis Lacaze, Florence Dalenc, Laurence Gladieff
Publikováno v: Cancer Research. 75:P4-07
Backgroud: Clinicians need new predictive biomarkers of response to therapy hormonal in patients with hormone receptor-positive (HR+) breast cancer (BC). Tumor-associated miRNAs are interesting new markers. Several data indicate the extensive alterat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::54df7cb63cc830524bb60c2cdfdf49de
https://doi.org/10.1158/1538-7445.sabcs14-p4-07-08
Zobrazit plný text záznamu
5
Iron homeostasis and anemia markers in early breast cancer
Autor: Anna Durigova, William Jacot, Pierre-Jean Lamy
Publikováno v: Clinica Chimica Acta
Clinica Chimica Acta, Elsevier, 2014, 434, pp.34--40. ⟨10.1016/j.cca.2014.04.011⟩
Iron plays a fundamental role in cell life and its concentration in living organisms is precisely regulated. Different molecules for iron storage and transport are used to maintain its intracellular homeostasis which is often altered in cancer cells.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8824852f422ebca36e39ee77bf0b54e8
https://doi.org/10.1016/j.cca.2014.04.011
Zobrazit plný text záznamu
6
Abstract P6-09-10: Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxy vitamin D levels in early breast cancer patients: A randomized phase III study
Autor: L. Roca, J-P Bleuse, William Jacot, Anna Durigova, S Pouderoux, S. Mirr, S. Gallet, P-J Lamy, Nelly Firmin, Delphine Topart, Gilles Romieu
Publikováno v: Cancer Research. 73:P6-09
Purpose: Only a minority of patients with early breast cancer (EBC) treated with adjuvant or neoadjuvant chemotherapy have sufficient baseline vitamin D. The current recommendations regarding daily vitamin D supplementation appears too low to correct
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ecf42d8212a5601e0743bec3399f62d4
https://doi.org/10.1158/0008-5472.sabcs13-p6-09-10
Zobrazit plný text záznamu
7
Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study
Autor: Anna Durigova, L. Roca, Nelly Firmin, Pierre-Jean Lamy, William Jacot, Véronique D'Hondt, S. Gallet, Stéphane Pouderoux, L. Abach, Jean-Pierre Bleuse, Gilles Romieu, Delphine Topart, S. Mirr
Publikováno v: Annals of Oncology
Annals of Oncology, Elsevier, 2016, 27 (7), pp.1235-1241. ⟨10.1093/annonc/mdw145⟩
Background A minority of early breast cancer (EBC) patients treated with adjuvant or neoadjuvant chemotherapy have sufficient baseline vitamin D (vitD) level. This randomized phase III study assessed the safety and efficacy of a tailored, high-dose,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9818825507d838c4947caab8c9a480e8
https://hal.umontpellier.fr/hal-02296725
Zobrazit plný text záznamu
9
Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study
Autor: Mélodie Dell’Ova, Anna Durigova, William Jacot, Séverine Guiu, Khedidja Bekhtari, L. Roca, Florence Dalenc, Eleonora De Maio, Stéphane Pouderoux, Frédéric Pinguet
Publikováno v: Bmc Cancer, vol. 15, no. 1, pp. 659
BMC Cancer
BACKGROUND: Our retrospective, international study aimed at evaluating the activity and safety of eribulin mesylate (EM) in pretreated metastatic breast cancer (MBC) in a routine clinical setting. METHODS: Patients treated with EM for a locally advan
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cd9e58b302e38fb9348b9607fcd1807
https://doi.org/10.1186/s12885-015-1673-3
Zobrazit plný text záznamu
10
Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and soluble transferrin receptor quantification
Autor: Anna, Durigova, Pierre-Jean, Lamy, Simon, Thezenas, Stephane, Pouderoux, Frédéric, Montels, Gilles, Romieu, Marian, Gutowski, William, Jacot
Publikováno v: Clinical chemistry and laboratory medicine. 51(9)
Anemia, a frequent and deleterious condition in patients with cancer, is mainly caused by chemotherapy toxicity, iron deficiency, or inflammation. We evaluated the baseline iron metabolism biomarkers and their association with anemia occurrence durin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::96e11039ef567b14e698ccd49d6087db
https://pubmed.ncbi.nlm.nih.gov/23787470
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje